Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
42.46
+0.41 (0.96%)
Market open: Aug 12, 2026, 3:03 PM EDT
40.87
-1.18 (-2.81%)
Previous after-hours: Aug 11, 2026, 7:42 PM EDT
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Name | Position |
|---|---|
| Mr. David C. Krempa | Chief Business Officer |
| Mr. James R. Gruber CPA | Consultant |
| Mr. Scott Grossenbach | Senior Vice President of Sales Operations |
| Mr. Sean E. Brynjelsen | President, CEO & Director |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-05 | 8-K | eton20260803_8k.htm |
| 2026-08-04 | 8-K | eton20260731_8k.htm |
| 2026-07-29 | 8-K | eton20260723_8k.htm |
| 2026-06-09 | 8-K | eton20260409_8k.htm |
| 2026-05-19 | 8-K | eton20260518_8k.htm |
| 2026-05-14 | 8-K | eton20260322_8k.htm |
| 2026-05-14 | 10-Q | eton20260331_10q.htm |
| 2026-05-01 | 8-K | eton20260429_8k.htm |
| 2026-04-27 | 8-K | eton20260401_8k.htm |
| 2026-04-24 | DEF 14A | eton20251124_def14a.htm |